Long-term efficacy of CAR T-cell therapy in patients who relapsed after transplantation. (A-B) The 102 CR patients who received CAR T-cell therapy were divided into 2 groups: those who relapsed after transplant and those without previous transplant. Patients with a history of previous transplantation had a lower 1-year OS and LFS than the group without previous transplant (OS: 30.5% vs 79.2%; HR, 5.27; P = .009; 95% CI, 1.51-18.48; LFS: 25.4% vs 69.4%; P = .011; HR, 0.23; 95% CI, 0.07-0.71).